+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.

Age: 18Years +All GendersPhase 1
26 locations
P

Actively Recruiting

Pancreatic adenocarcinoma is a very serious cancer with few treatment options for those whose tumors cannot be surgically removed. Researchers are evaluating the safety and tolerability of using Yttrium-90 90Y glass microspheres delivered directly into the arteries feeding the tumor to target radiation treatment. This Phase I clinical trial aims to assess radiation dose distribution, side effects, and early signs of how the tumor responds to this selective arterial radioembolization. Participants will first undergo imaging and dose planning using a special scan called SPECTCT with 99mTc-labeled macroaggregated albumin to understand how the microspheres will distribute. Then, the Yttrium-90 microspheres will be infused into the tumors arteries through a catheter, with doses gradually increased in small groups of patients. After treatment, further imaging and dosimetry tests will measure how the radiation was distributed and evaluate the tumors response. During the study, participants will be closely monitored for safety and side effects for up to 8 weeks after the procedure. Radiation exposure will be assessed immediately after treatment, and tumor response will be evaluated at 8 weeks. The total study participation may last until the final assessments are completed, with careful follow-up to understand the impact of the treatment and any adverse effects.

Age: 18Years - 75YearsAll GendersPhase 1
1 location
O

Actively Recruiting

Researchers are conducting a multicenter observational study in the Russian Federation focusing on patients with aggressive high-volume metastatic hormone-sensitive prostate cancer mHSPC. The study aims to analyze treatment patterns and evaluate homologous recombination repair mutations HRRm using circulating tumor DNA ctDNA. The population includes those with high-aggressive Gleason score 8-10 and high-volume disease, with known tumor HRRm status determined from routine tumor samples. Approximately 230 patients will be enrolled, equally representing HRRm and wild-type HRR HRRwt groups. This study involves no additional procedures beyond routine clinical practice. Data collection includes two visits the baseline visit gathers demographic, clinical, and treatment history from medical records and patient interviews, as well as blood samples for ctDNA and HRRm testing performed centrally. The final visit occurs at disease progression or after about 12 months to collect follow-up data on progression to metastatic castration-resistant prostate cancer mCRPC and further treatments. Follow-up data may be collected by telephone if the patient cannot visit the study site. Participants contribute data through medical record reviews, interviews, and routine blood sampling. Researchers will monitor various outcomes including treatment types and durations, progression timelines, mutation presence in ctDNA, and clinical characteristics like Gleason scores and metastasis sites. Data will be entered into electronic records, with the study lasting about 36 months until enrollment and follow-up are complete.

Age: 18Years +MALE
28 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter, prospective observational study focusing on molecular profiling and first-line treatment approaches for patients with aggressive advanced endometrial cancer stage III-IV in the Russian Federation. The study aims to collect real-world data on the prevalence of specific molecular markers such as POLE mutations, mismatch repair status, p53 abnormalities, HER2, and PD-L1 expression, alongside demographic and clinical characteristics of these patients. The study will include approximately 500 female patients newly diagnosed with aggressive advanced endometrial cancer subtypes who have available biopsy or postoperative archival tumor samples. No additional procedures beyond routine clinical practice will be performed. Molecular testing will be conducted centrally using immunohistochemistry and genetic sequencing techniques on tumor samples. Data collection will occur during two visits the baseline visit to gather demographic, clinical, and treatment information, and a follow-up visit six months later or at disease progression to collect further treatment and progression data. Participants will have their clinical and molecular data entered into electronic records by study physicians. The study will monitor several primary outcomes related to the rates of molecular marker positivity over 24 months and secondary outcomes including chemotherapy use, disease progression, patient demographics, and tumor characteristics over 33 months. The total study duration is expected to be about 27 months or until 500 eligible patients have been enrolled and their data collected, including follow-up.

Age: 18Years +FEMALE
19 locations
O

Actively Recruiting

Researchers are evaluating the efficacy and safety of BCD-248 as a treatment for patients with relapsed or refractory multiple myeloma, a condition where the disease has returned or is resistant to previous therapies. This open-label phase 2 clinical study aims to assess the overall response rate and other important outcomes in this patient population. The study is sponsored by Biocad and focuses on patients who have received multiple prior treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy. Participants will receive BCD-248 administered subcutaneously. The study monitors various outcomes including overall response rate up to 24 weeks and progression-free survival up to 104 weeks, among others, over a total duration extending to about 3.7 years for some measures. Pharmacokinetic parameters like Cmax, Cmin, AUC0-t, and Ctrough will be tracked shortly after administration and up to 6 months. Additional assessments include measurement of soluble BCMA levels and the presence of binding and neutralizing antibodies. During the study, participants will undergo regular evaluations including disease assessments based on International Myeloma Working Group criteria, safety monitoring for adverse events, and laboratory tests. Long-term follow-up will include evaluation of response duration, time to response and progression, and overall survival. The study started in December 2024 and is expected to continue until July 2028, providing extended observation for participant outcomes and safety.

Age: 18Years +All GendersPhase 2
20 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

Age: 18Years - 74YearsFEMALEPhase 2
47 locations
P

Actively Recruiting

Researchers are evaluating stereotactic ablative radiation therapy SABR for patients with metastatic cancer who have 6 to 10 metastatic sites in bones and internal organs. This study focuses on patients with persistent or progressive metastatic tumors who continue their current drug therapy. The goal is to assess the safety and effectiveness of radiation treatment for these patients, as current radiation approaches have shown benefits for those with fewer metastases, but less is known for patients with more than five metastatic sites. The study uses stereotactic radiation therapy applied to each metastatic site in ablative doses. Treatment planning involves advanced imaging techniques like three- or four-dimensional computed tomography, fixation devices, and contouring of targets and organs at risk. Various radiation doses and schedules are tailored depending on tumor location, such as lungs, brain, liver, bones, and adrenal glands. Radiation sessions use a linear accelerator with real-time visual control and special breathing techniques when needed. The radiation course lasts between 1 to 8 working days following up to 3 days of preparation. Participants undergo a thorough pre-treatment examination, followed by detailed radiation therapy. After treatment, they are monitored at 3, 6, 9, and 12 months, then every 6 months for up to 5 years. Researchers collect and analyze data on treatment safety and effectiveness, including progression-free survival, local control, overall survival, and timing of changes in chemotherapy. Participants continue their regular cancer care and provide informed consent to join the study.

Age: 18Years +All GendersPhase 2
1 location
E

Actively Recruiting

Researchers are studying if preoperative proton therapy PPT is tolerable and safe for adults with high-grade brain gliomas, including glioblastomas. These aggressive brain tumors have poor survival rates and limited treatment advances. The trial aims to determine the highest safe dose of PPT and its effects on surgery, clinical outcomes, and safety. Participants receive preoperative proton stereotactic radiotherapy targeting the tumor with increasing dose levels in small groups of patients. This is followed by surgical removal of the tumors contrast-enhancing part using advanced imaging and monitoring techniques. After surgery, MRI scans assess tumor removal, and a follow-up evaluation occurs 3-4 weeks later. Then, standard chemoradiotherapy with proton beams and temozolomide chemotherapy begins 4-6 weeks after surgery, followed by maintenance chemotherapy for up to 12 cycles or until disease progression. During the study, participants undergo clinical, radiological, and morphological assessments to evaluate treatment effects and safety. Follow-up exams happen monthly after chemoradiotherapy and then quarterly during the first year. The main outcome measured is radiation-induced toxicity over 12 months, along with clinical effects, maximal irradiation dose, and postoperative safety. The total participation period extends up to several years, including standard treatment and monitoring.

Age: 18Years +All GendersPhase 1
1 location
S

Actively Recruiting

Researchers are evaluating stereotactic radiation therapy as a treatment for patients with oligometastatic cancer, which means having one to five metastatic tumors in bones or internal organs. The study aims to improve treatment effectiveness compared to the usual palliative care, which includes chemotherapy and less intense radiation therapy. This trial includes adult patients with various tumor locations who have completed a current chemotherapy line and have specific cancer stages T1-4, N0-3, M0-1. Participants are randomly assigned to receive either stereotactic ablative radiation therapy targeting each metastatic site or standard palliative radiation therapy or chemotherapy alone. The stereotactic radiation uses detailed imaging and planning to deliver focused, high-dose radiation over several sessions depending on tumor location and size. The study involves pre-treatment imaging and planning, radiation treatment sessions lasting from one to eight working days, and follow-up visits scheduled at 3, 6, 9, 12, 18, and 24 months. During the study, participants undergo comprehensive examinations before treatment, imaging scans, and radiation sessions with precise targeting methods. Researchers will monitor progression-free survival and time before changing chemotherapy lines as primary outcomes, along with side effects, overall survival, metastasis control, and quality of life assessments. Data collection and analysis will continue through follow-up visits extending up to two years after treatment completion.

Age: 18Years +All GendersPhase 2Phase 3
1 location
O

Actively Recruiting

Researchers are conducting a multicenter observational study to examine treatment methods and the presence of HER2 positive status in various stages of bladder cancer, as well as PD-L1-positive status in metastatic bladder cancer among adult patients in the Russian Federation. The study includes patients with non-muscle-invasive bladder cancer NMIBC, muscle-invasive bladder cancer MIBC, or metastatic bladder cancer mBC to better understand how these biomarkers and treatments vary by disease stage. This study does not involve any new treatments or changes to routine care. Instead, it collects information from medical records and existing tumor tissue samples obtained during standard clinical procedures. The study will include about 600 adult patients from around 30 oncology centers, divided evenly into three groups based on their bladder cancer stage. Data collection happens during a single routine clinical visit without additional follow-up. Participants provide medical history, demographic details, and information on treatments they have received. Tumor tissue samples are sent to a central laboratory for testing. Researchers will analyze these data to measure treatment patterns and biomarker prevalence, including HER2 and PD-L1 status. The study aims to complete enrollment within 18 months or once 600 patients are included, with no ongoing patient visits beyond the initial data collection.

Age: 18Years +All Genders
20 locations